Clinical Trial Update: Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine [Phase 3]

View source ↗

Summary

An open-label Phase 3 trial evaluating BOTOX (botulinum toxin type A) for chronic migraine in Chinese patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Allergan | Conditions: Migraine Disorders | Phase 3 | Status: WITHDRAWN